At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
The 2025 ACR Awards of Distinction
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
The 2025 ARP President’s & Merit Awards
Meet the 2025 ARP President’s & Merit Award recipients honored for their significant contributions to rheumatology research, education & patient care.
The ACR Names 16 New Masters
The ACR recognizes 16 members with its highest honor. See the 2025 class of ACR Masters & read their personal reflections on this career milestone.
ACR Honors Distinguished Fellows: Class of 2025
Meet the 10 clinical & research fellows named 2025 ACR Distinguished Fellows. Learn what this prestigious honor means to them & their work.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Sjögren’s Disease: More Than Just a Syndrome
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 103
- Next Page »